Dezhan Healthcare Valuation
Is 000813 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 000813 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 000813's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 000813's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 000813?
Key metric: As 000813 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 000813's PS Ratio? | |
|---|---|
| PS Ratio | 12.9x |
| Sales | CN¥517.42m |
| Market Cap | CN¥6.69b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.8x |
| Enterprise Value/EBITDA | 174.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 000813's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 4.5x | ||
000989 Jiuzhitang | 2.4x | n/a | CN¥6.5b |
300267 Hunan Er-Kang Pharmaceutical | 5.3x | n/a | CN¥6.3b |
000566 Hainan Haiyao | 6.4x | n/a | CN¥6.6b |
300147 Xiangxue PharmaceuticalLtd | 4x | n/a | CN¥8.3b |
000813 Dezhan Healthcare | 13.3x | n/a | CN¥6.9b |
Price-To-Sales vs Peers: 000813 is expensive based on its Price-To-Sales Ratio (13.3x) compared to the peer average (4.5x).
Price to Sales Ratio vs Industry
How does 000813's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?
| 6 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
600664 Harbin Pharmaceutical Group | 0.6x | n/a | US$1.28b |
000411 Zhejiang Int'l GroupLtd | 0.2x | n/a | US$777.77m |
000153 Anhui Fengyuan Pharmaceutical | 0.7x | n/a | US$410.69m |
600781 FUREN Group PharmaceuticalLtd | 0.3x | n/a | US$66.91m |
| 6 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: 000813 is expensive based on its Price-To-Sales Ratio (13.3x) compared to the CN Pharmaceuticals industry average (3.5x).
Price to Sales Ratio vs Fair Ratio
What is 000813's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 12.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000813's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Sichuan Kelun Pharmaceutical
CN¥48.4b
Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.
2422
CN¥30.51
7D
2.2%
1Y
7.6%
Dong-E-E-JiaoLtd
CN¥36.4b
Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.
423
CN¥56.59
7D
-2.4%
1Y
12.8%
China Resources Double-Crane PharmaceuticalLtd
CN¥21.4b
China Resources Double-Crane Pharmaceutical Co.,Ltd.
600062
CN¥20.91
7D
-1.8%
1Y
14.6%